

# 2023 RESEARCH FAST FACTS

## Precision Medicine: Overview



### RESEARCH INVESTMENT AT A GLANCE: (1982-2023)

More than **\$340** million in over **720** research grants and over **125** clinical trials focused on precision medicine

**67%** focus on treatment



### ABOUT PRECISION MEDICINE

Cancer care has moved away from a “one-size-fits-all” approach towards a more individualized approach called [precision medicine](#). Precision medicine, also called personalized medicine, tailors disease prevention and treatment by taking into account the unique differences in an individual’s genes, lifestyle, and environment. This allows researchers to predict more accurately which treatments and prevention strategies will work best among diverse groups of people, addressing the complexity of the disease as well as its many types and causes.

Learn more about Precision Medicine [here](#).

### WHAT WE’RE INVESTIGATING



Developing a diverse biobank of normal breast tissue and breast cancer specimens as a resource for researchers to enable advances in personalized medicine.



Identifying biomarkers associated with different responses to chemotherapy in Black women with triple negative breast cancer (TNBC) versus other populations to develop personalized TNBC treatments.



Conducting a clinical trial to test whether a liquid biopsy (blood test) can match people with drug resistant hormone receptor-positive (HR+) breast cancer to new therapies tailored to their tumors.

### IN THE RESEARCH PIPELINE:

Nearly **1700** potential **new research discoveries** (drugs, biomarkers, devices, etc.) focused on precision medicine and/or treatment.

### SPOTLIGHT



Triple negative breast cancer (TNBC) patients have limited treatment options, and with Komen support Dr. Nathan Merrill is looking to change that. [Read more about his innovative project](#), where he is testing different drug combinations with the goal of identifying new and effective drug combinations for TNBC patients.

### WHAT WE’VE LEARNED FROM KOMEN-FUNDED RESEARCH

- A [novel tool](#) developed through a collaborative effort between Komen and the Inflammatory Breast Cancer Research Foundation (IBCRF) in partnership with the Milburn Foundation may be able to help health care providers identify and diagnose IBC more accurately.
- Different types of breast cancer have mutations in the *PIK3CA* gene, which could [help identify](#) tumors that best respond to therapies that target the PI3K protein that drives growth of these breast cancers.
- A [new experimental drug](#) that targets a protein called TGFβ may prevent certain types of breast cancer.



**LEARN MORE ABOUT BREAST CANCER**

**MORE KOMEN-FUNDED RESEARCH STORIES**

**GET INVOLVED & SUPPORT RESEARCH**